Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epithelial-mesenchymal transition (EMT) and the histone methyltransferase Enhancer of Zeste Homologue 2 (EZH2) are important regulators of lung cancer progression and metastasis.
|
31042721 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the combination of si-EZH2 and inhibitor was used to further verify whether microRNA-130-5p could promote cell metastasis and invasion of lung cancer by targeting EZH2.
|
31773700 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to investigate the link between enhancer of zeste homolog 2 (EZH2) and histone deacetylase (HDAC) in preclinical studies and in human lung cancer tissue microarrays.
|
31456359 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhancer of zeste homolog 2 (EZH2) is reported to be involved in lung cancer pathogenesis via the epigenetic regulation of various genes.
|
30343006 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
At the same time, EZH2 expression in LCa tissues was also remarkably up-regulated relative to adjacent tissues, and it was positively correlated with the expression of MSTO2P.
|
31081092 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The molecular mechanisms associated with EZH2 expression, generate a dysregulation of cell apoptosis, mesenchymal transition, and cell invasiveness in bronchial epithelial cells, encouraging the progression of airway inflammation toward lung cancer in COPD patients.
|
31666665 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.
|
30487290 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer.
|
30223276 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2.
|
30555330 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, the regulation of miRNAs and EZH2 has been demonstrated in other cancer researches, like lung cancer, pancreatic cancer, leukemia and so on.
|
28322158 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhancer of zeste homolog 2 (EZH2), the critical component of polycomb group protein family, has been demonstrated to be overexpressed in various types of human cancer, including hepatocellular carcinoma, breast, bladder and lung cancer.
|
29435024 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Better understanding regarding the interaction and regulatory network will provide new insights on lncRNA- or EZH2-based therapeutic development in lung cancer.
|
30519315 |
2018 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.
|
28314309 |
2017 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of miR-21 and EZH2 on the biological behavior of human lung cancer stem cells <i>in vitro</i>.
|
29156731 |
2017 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on major mechanisms of epigenetic regulation mainly in lung cancer with recent data on EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit ), the catalytic subunit of the PRC2 (Polycomb Group PcG), that behaves as an oncogene in lung cancer associated with gene repression, non-coding RNAs and the epitranscriptome.
|
28672805 |
2017 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combined hazard ratios suggested that EZH2 overexpression was associated with poor prognosis of overall survival (OS) (HR = 1.68, 95% CI: 1.42-1.93) in patients with lung cancer.
|
26754405 |
2016 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer.Cancer Discov; 6(9); 1006-21.
|
27312177 |
2016 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Developing EZH2-Targeted Therapy for Lung Cancer.
|
27587466 |
2016 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our work defines EZH2 as a downstream effector of KRAS signaling and offers a rationale for combining EZH2 inhibitory strategies with MEK-ERK- or PI3K/AKT-targeted therapies to treat lung cancer patients, as stratified into distinct treatment groups based on specific KRAS mutations.
|
26676756 |
2016 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We for the first time proposed the role interleukin-1β-mir-101-EZH2 axes in the particle-induced lung cancer.
|
25428391 |
2015 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functionally, EZH2 K348 acetylation enhances its capacity in suppression of the target genes and promotes lung cancer cell migration and invasion.
|
25800736 |
2015 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the mechanisms of regulation and role associated with enhancer of zeste homolog 2 (EZH2) expression in lung cancer cells.
|
24850841 |
2014 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, Nrf2 seems to be essential for the hyper proliferation of lung cancer cells in the absence of EZH2.
|
24928441 |
2014 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we showed that EZH2 was up-regulated in lung cancer and had a positive correlation with pathologic stage, nodal involvement in lung cancer patients.
|
24132606 |
2013 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although enhancer of zeste homolog 2 (EZH2) has been associated with both non-small cell and small-cell lung cancers (SCLCs), current observations suggest different mechanisms of EZH2 activation and overexpression in these lung cancer types.
|
23857401 |
2013 |